מדינה: קנדה
שפה: אנגלית
מקור: Health Canada
IBUPROFEN
MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC
M01AE01
IBUPROFEN
400MG
CAPSULE
IBUPROFEN 400MG
ORAL
12/16/24/50/100/144/165/180
OTC
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Active ingredient group (AIG) number: 0108883002; AHFS:
CANCELLED POST MARKET
2019-07-31
Page 1 of 37 PRODUCT MONOGRAPH SUPER STRENGTH MOTRIN® IB LIQUID GELS Ibuprofen Capsules 400 mg Analgesic /Antipyretic McNeil Consumer Healthcare DATE OF PREPARATION: division of Johnson & Johnson Inc. October 7, 2008 88 McNabb Street Markham, Canada L3R 5L2 DATE OF REVISION: September 13, 2012 www.motrin.ca CONTROL NUMBER: 156425 Page 2 of 37 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ....................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................. 3 INDICATIONS AND CLINICAL USE ................................................................................... 3 CONTRAINDICATIONS ........................................................................................................ 4 WARNINGS AND PRECAUTIONS ....................................................................................... 5 ADVERSE REACTIONS ......................................................................................................... 9 DRUG INTERACTIONS ....................................................................................................... 13 DOSAGE AND ADMINISTRATION ................................................................................... 16 OVERDOSAGE ...................................................................................................................... 16 ACTION AND CLINICAL PHARMACOLOGY.................................................................. 17 STORAGE AND STABILITY ............................................................................................... 20 SPECIAL HANDLING INSTRUCTIONS ............................................................................ 20 DOSAGE FORMS, COMPOSITION AND PACKAGING .................................................. 20 PART II: SCIENTIFIC INFORMATION ............................................................................. 21 PHARMACEUTICAL INFORMATION ........................................................... קרא את המסמך השלם